Stock analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ - Get Free Report) in a research note issued to investors on Monday. The brokerage set a "hold" rating on the medical research company's stock.
Enzo Biochem Stock Performance
ENZ stock traded up $0.01 during mid-day trading on Monday, hitting $1.06. 88,293 shares of the company were exchanged, compared to its average volume of 100,898. Enzo Biochem has a 1-year low of $0.93 and a 1-year high of $1.50. The firm's 50 day simple moving average is $1.10 and its 200 day simple moving average is $1.11.
Hedge Funds Weigh In On Enzo Biochem
Several hedge funds have recently made changes to their positions in ENZ. BBR Partners LLC acquired a new position in Enzo Biochem during the third quarter valued at approximately $112,000. Renaissance Technologies LLC grew its stake in shares of Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company's stock valued at $2,725,000 after buying an additional 64,417 shares in the last quarter. XTX Topco Ltd increased its holdings in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company's stock worth $31,000 after buying an additional 13,735 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company's stock worth $413,000 after purchasing an additional 11,742 shares during the last quarter. 36.90% of the stock is owned by institutional investors.
Enzo Biochem Company Profile
(
Get Free Report)
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Read More
Before you consider Enzo Biochem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enzo Biochem wasn't on the list.
While Enzo Biochem currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
